Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events
New England Journal of Medicine2008Vol. 359(12), pp. 1225–1237
Citations Over TimeTop 1% of 2008 papers
Salim Yusuf, Hans‐Christoph Diener, Ralph L. Sacco, Otto W. Witte, Stephanie Ôunpuu, William A Lawton, Yuko Palesch, Renée H. Martin, Gregory W. Albers, Philip M. Bath, Natan M. Bornstein, Bernard P.L. Chan, Christopher Chen, Luı́s Cunha, Björn Dahlöf, Jacques De Keyser, Geoffrey A. Donnan, Conrado J. Estol, Philip B. Gorelick, Vivian Gu, Karin Hermansson, Lutz Hilbrich, Markku Kaste, Chuanzhen Lü, Thomas Machnig, Prem Pais, Robin Roberts, Veronika Skvortsova, Philip Teal, Danilo Toni, Cam P. VanderMaelen, Thor Voigt, Michael A. Weber, Byung‐Woo Yoon
Abstract
Therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years did not significantly lower the rate of recurrent stroke, major cardiovascular events, or diabetes. (ClinicalTrials.gov number, NCT00153062.)
Related Papers
- → Telmisartan Promotes Potential Glucose Homeostasis in Stroke-Resistant Spontaneously Hypertensive Rats via Peroxisome Proliferator-Activated Receptor .γ Activation(2015)5 cited
- → THE EFFECTS NEUROPROTECTION OF TELMISARTAN ON STROKE WITH HYPERTENSION(2020)3 cited
- → Relationship between Telmisartan Dose and Glycaemic Control in Japanese Patients with Type 2 Diabetes Mellitus and Hypertension(2012)2 cited
- Clinical Study on Effect of Telmisartan on Hypertension(2007)
- Synthesis of telmisartan(2003)